| | 
Part, Chapter, Paragraph
1 I, 2. 4 | interventions and thrombolytic therapy). Apparently, while these
2 I, 2. 10. 2| discovery and drug delivery and therapy, for biomarker discovery,
3 II, 5. 1. 2| biomedicine and evidence-based therapy. Patient-centeredness is
4 II, 5. 1. 3| pharmacological and physical therapy .~ ~
5 II, 5. 2. 3| identifying thrombolytic therapy use from hospital in-patient
6 II, 5. 3. 2| practices in diagnosis and therapy so as to interpret these
7 II, 5. 3. 7| integrate these drugs into therapy programs. It is necessary
8 II, 5. 4. 1| necessitating renal replacement therapy: dialysis or transplantation);~
9 II, 5. 4. 2| transplantation (renal replacement therapy in patients with diabetes/
10 II, 5. 4. 2| transplantation (renal replacement therapy) in patients with diabetes /
11 II, 5. 4. 2| transplantation (renal replacement therapy) per 100,000 individuals
12 II, 5. 5. 3| Despite improvements in drug therapy and in mental health services,
13 II, 5. 5. 3| psychotherapy and psycho-social therapy. While nearly all people
14 II, 5. 5. 3| and cognitive behavioural therapy. For other treatment approaches,
15 II, 5. 5. 3| practice of focusing on drug therapy and neglecting psychosocial
16 II, 5. 5. 3| further improvement of drug therapy;~· ensure the delivery of
17 II, 5. 5. 3| and cognitive behaviour therapy. Psychol Med 32(5):763-82.~
18 II, 5. 5. 3| Escalating Immunomodulatory Therapy of MS Consensus Paper~·
19 II, 5. 5. 3| The multiple sclerosis therapy consensus group (MSTCG)
20 II, 5. 5. 3| Sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG)
21 II, 5. 5. 3| MSTCG (Multiple sclerosis therapy consensus group) and Rieckmann
22 II, 5. 5. 3| Escalating immunomodulatory therapy of multiple sclerosis. Update.
23 II, 5. 5. 3| MSTCG (Multiple sclerosis therapy consensus group) (2007): “
24 II, 5. 5. 3| Escalating Immunomodulatory Therapy of MS Consensus Paper ,
25 II, 5. 5. 3| MSTCG~Multiple Sclerosis Therapy Consensus Group~PML~Progressive
26 II, 5. 5. 3| Research, Diagnosis and Therapy of Parkinson’s Disease -
27 II, 5. 5. 3| 1994): Epidemiology and therapy of Parkinson disease in
28 II, 5. 5. 3| Brien PC (1993): Levodopa therapy and survival in idiopathic
29 II, 5. 6.Acr| HRT~Hormone Replacement Therapy~NSAIDs~Non-steroidal anti-inflammatory
30 II, 5. 6. 3| but hormone replacement therapy (HRT) is associated with
31 II, 5. 6. 3| controlled on symptomatic therapy alone. Spontaneous remission
32 II, 5. 7.Acr| Framework~RRT~Renal Replacement Therapy~WHO~World Health Organization~ ~
33 II, 5. 7. 1| Data on renal replacement therapy (RRT) for ESRD in children
34 II, 5. 7. 1| cost-effective renal replacement therapy (White et al, 2008). The
35 II, 5. 7. 1| Classification Based on Severity and Therapy~ ~ ~Stage~Description~GFR*~(
36 II, 5. 7. 5| Accessibility of dialysis therapy is possible in 92 dialysis
37 II, 5. 7. 7| marker, and a new target for therapy. Kidney Int Suppl 2005 Sep;(
38 II, 5. 7. 7| incidence of renal replacement therapy in developed countries come
39 II, 5. 7. 7| Financing for renal replacement therapy in Italy: an evolving reality.
40 II, 5. 7. 7| incidence of renal replacement therapy for end-stage renal disease
41 II, 5. 8. 1| needing long term oxygen therapy and assisted ventilation,
42 II, 5. 9. 3| prophylaxis, maintenance therapy etc.) for preventing heavier
43 II, 5. 9. 5| the cost-benefit ratio of therapy and management measures,
44 II, 5. 9. 6| impact the disease and its therapy as perceived by patients (
45 II, 5. 11. 4| time lost for daily topical therapy and skin care in many skin
46 II, 5. 15. 4| the Council on advanced therapy medicinal products (European
47 II, 5. 15. 4| traceability of advanced therapy products.~ ~At Member State
48 II, 5. 15. 6| November 2007 on advanced therapy medicinal products and amending
49 II, 6. 3. 3| highly active anti-retroviral therapy (HAART). More work is needed
50 II, 6. 3. 3| improve accessibility of this therapy to PLHIV. Counselling and
51 II, 6. 3. 4| progression, while preventive therapy reduces this risk. The BCG
52 II, 7. 4. 6| of cognitive behavioural therapy. Trends towards benefits
53 II, 7. 4. 6| emergency cards, dialectical therapy and specific medicinal products.~ ~
54 II, 9 | with hormone replacement therapy (Beral, 2003), and higher
55 II, 9. 3. 1| involves androgen ablation therapy, has a marked effect on
56 II, 9. 3. 1| changes requiring replacement therapy occur.~ ~While androgen
57 II, 9. 3. 1| candidates for androgen therapy. Various guidelines have
58 II, 9. 3. 1| with hormone replacement therapy (Beral, 2003), and higher
59 II, 9. 3. 1| and hormone-replacement therapy in the Million Women Study.
60 II, 9. 3. 1| ART~Androgen Replacement Therapy~BMD~Bone Mineral Density~
61 II, 9. 4. 3| diagnostic investigations, therapy input and outpatient review (
62 II, 9. 5. 3| with hormone replacement therapy (Beral, 2003), and higher
63 II, 9. 5. 6| and hormone-replacement therapy in the Million Women Study.
64 III, 10. 2. 1| pharmacotherapy and behavioral therapy. These are most effective
65 III, 10. 2. 1| pharmacotherapy and behavioral therapy probably yields best results.~ ~
66 III, 10. 2. 1| Nicotine replacement therapy (NRT) in the form of patches,
67 III, 10. 2. 1| integration of behavioral therapy can increase the quitting
68 III, 10. 2. 4| approaches to prevention and therapy (Khoury, 1996; Brand, 2002;
69 III, 10. 2. 4| individual prevention and therapy develop the more the use
70 III, 10. 4. 2| antimicrobials commonly used in human therapy. This is especially the
71 III, 10. 6. 2| interventions and thrombolytic therapy). Apparently, while these
72 IV, 11. 3. 2| Community level by ATC-1 therapy area (2004-2010)~ ~The expected
73 IV, 11. 5. 5| demand of organ replacement therapy by increasing donation rates.~-
74 IV, 12. 2 | pharmacotherapy and behavioral therapy. Only 3% of smokers manage
75 IV, 12. 2 | pharmacotherapy and behavioral therapy probably yields best results.
76 IV, 12. 2 | results. Nicotine replacement therapy (NRT) in form of patches,
77 IV, 12. 2 | integration of behavioral therapy can increase the quitting
78 IV, 12. 10 | Detoxification, long term therapy and rehabilitative measures
79 IV, 12. 10 | on primary prevention and therapy of eating disorders (see www. – “
80 IV, 12. 10 | epizootic diseases. Gene therapy as well is closely controlled:
81 IV, 12. 10 | Committee for Somatic Gene Therapy of the German Medical Association (
82 IV, 12. 10 | Hypertension Diagnostics and Therapy /Croatian edition/~Interactions
|
|
| |
